Skip to main navigation Skip to search Skip to main content

Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis

  • ECNP Physical And meNtal Health Thematic Working Group (PAN-Health)
  • University of Ottawa
  • Charité – Universitätsmedizin Berlin
  • AULSS 3 Serenissima
  • University of Naples Federico II
  • WebMD Global LLC
  • Semmelweis University
  • Institute of Psychiatry and Neurosciences of Paris (IPNP)
  • Université Paris Cité
  • Karolinska Institutet
  • Stockholm City Council
  • University of Eastern Finland
  • University of Southampton
  • Solent NHS Trust
  • New York University
  • University of Bari
  • Linköping University
  • Aalborg University
  • University of Manchester
  • King's College London
  • University of Pavia
  • South London and Maudlsey (SLaM) NHS Foundation Trust
  • Ludwig Maximilian University of Munich
  • University of Groningen
  • University of Tromsø – The Arctic University of Norway
  • Parc Sanitari Sant Joan de Déu
  • Örebro University
  • University of Tartu
  • The Swedish Institute for Health Economics
  • University of Cagliari
  • University Hospital of Cagliari
  • Dalhousie University
  • University of Copenhagen
  • Pomeranian Medical University in Szczecin
  • South London and Maudsley NHS Foundation Trust
  • KU Leuven
  • Aix-Marseille Université
  • Fondation FondaMental
  • University of Barcelona
  • Zucker Hillside Hospital
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Research output: Contribution to journal › Review article › peer-review

22 Citations (Scopus)

Abstract

People with schizophrenia die prematurely, yet regional differences are unclear. PRISMA 2020-compliant systematic review/random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) versus any control group, and moderators, in people with ICD/DSM-defined schizophrenia, comparing countries and continents. We conducted subgroup, meta-regression analyses, and quality assessment. The primary outcome was all-cause mortality. Secondary outcomes were suicide-, /natural-cause- and other-cause-related mortality. We included 135 studies from Europe (n = 70), North-America (n = 29), Asia (n = 33), Oceania (n = 2), Africa (n = 1). In incident plus prevalent schizophrenia, differences across continents emerged for all-cause mortality (highest in Africa, RR=5.98, 95 %C.I.=4.09-8.74, k = 1, lowest in North-America, RR=2.14, 95 %C.I.=1.92-2.38, k = 16), suicide (highest in Oceania, RR=13.5, 95 %C.I.=10.08-18.07, k = 1, lowest in North-America, RR=4.4, 95 %C.I.=4.07-4.76, k = 6), but not for natural-cause mortality. Europe had the largest association between antipsychotics and lower all-cause mortality/suicide (Asia had the smallest or no significant association, respectively), without differences for natural-cause mortality. Higher country socio-demographic index significantly moderated larger suicide-related and smaller natural-cause-related mortality risk in incident schizophrenia, with reversed associations in prevalent schizophrenia. Antipsychotics had a larger/smaller protective association in incident/prevalent schizophrenia regarding all-cause mortality, and smaller protective association for suicide-related mortality in prevalent schizophrenia. Additional regional differences emerged in incident schizophrenia, across countries, and secondary outcomes. Significant regional differences emerged for all-cause, cause-specific and suicide-related mortality. Natural-cause death was homogeneously increased globally. Moderators differed across countries. Global initiatives are needed to improve physical health in people with schizophrenia, local studies to identify actionable moderators.
Original languageEnglish
Pages (from-to)55-69
Number of pages15
JournalEuropean Neuropsychopharmacology
Volume80
DOIs
Publication statusPublished - Mar 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antipsychotic
  • Geographical regions
  • Meta-analysis
  • Mortality
  • Schizophrenia
  • Systematic review

Fingerprint

Dive into the research topics of 'Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this